Related Experiment Video

Updated: May 20, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combined Use of Angiotensin Receptor Blockers and Calcium Channel Blockers in High-risk Hypertensive Populations: An

Li Gao1, Juan Cao1, Xianyong Zhou1

  • 1Cardiology Department, Taixing People's Hospital Affiliated to Yangzhou University.

Journal of Visualized Experiments : Jove
|May 18, 2026
PubMed

Insights

Combining angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) improved blood pressure control and vascular outcomes in high-risk hypertensive patients. This combination therapy shows promise for optimizing treatment strategies in hypertension management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • High-risk hypertensive patients often require complex treatment strategies.
  • Optimizing combination therapy with angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) is crucial for managing hypertension.
  • Current treatment guidelines emphasize individualized approaches for high-risk populations.

Purpose of the Study:

  • To evaluate the efficacy of combined ARB and CCB therapy versus monotherapy in high-risk hypertensive patients.
  • To assess the impact of combination therapy on cardiovascular and cerebrovascular events.
  • To determine the effects on blood pressure control, vascular function, and quality of life.

Main Methods:

  • Observational matched cohort study of 330 high-risk hypertensive patients (2018-2024).
  • Propensity score matching created three groups: ARB monotherapy (valsartan), CCB monotherapy (amlodipine), and combination therapy (valsartan/amlodipine).
  • Data collection included medical records, ambulatory blood pressure monitoring, ultrasounds, ECG, pulse wave velocity, and SF-36 questionnaires.

Main Results:

  • Combination therapy demonstrated advantages in blood pressure control compared to monotherapies.
  • The valsartan/amlodipine group showed improvements in vascular outcomes.
  • No specific data on cardiovascular/cerebrovascular events or quality of life differences were detailed, but trends favored combination therapy.

Conclusions:

  • Combined ARB and CCB therapy (valsartan/amlodipine) appears beneficial for high-risk hypertensive patients.
  • This combination may offer superior blood pressure control and vascular benefits.
  • Further prospective studies are recommended to validate these findings and confirm long-term efficacy and safety.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...